Feb 10, 2026 04:05PM
Feb 4, 2026 07:08AM
Feb 2, 2026 08:03AM
Feb 2, 2026 08:00AM
Mar 26, 2025 01:08PM
Mar 26, 2025 01:07PM
Feb 11, 2025 04:05PM Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
Jan 24, 2025 02:31PM
Jan 24, 2025 02:30PM
Jan 13, 2025 12:50PM
Jan 12, 2025 04:00PM
Jan 9, 2025 09:00AM
Nov 27, 2024 07:08AM
Nov 26, 2024 04:05PM Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Oct 29, 2024 04:05PM
Oct 16, 2024 06:54AM
Oct 16, 2024 06:03AM
Sep 16, 2024 02:01PM
Sep 16, 2024 08:45AM
Sep 16, 2024 08:45AM
Aug 6, 2024 04:05PM Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 6, 2024 08:30AM
Aug 6, 2024 08:30AM
Feb 14, 2024 08:30AM
Nov 2, 2021 04:05PM
Sep 20, 2021 11:30AM
Sep 20, 2021 11:30AM
Sep 17, 2021 04:24PM UPDATE: FDA Approves Exelixis's (EXEL) CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Sep 17, 2021 04:23PM
Aug 5, 2021 04:05PM
Aug 5, 2021 08:01AM
Aug 5, 2021 08:00AM
Apr 29, 2021 06:59AM
Jan 22, 2021 01:10PM
Jan 10, 2021 04:00PM Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
Nov 5, 2020 04:05PM
Nov 5, 2020 06:59AM
Oct 19, 2020 07:00AM
Oct 19, 2020 06:59AM
Dec 5, 2018 01:33AM
Nov 15, 2018 01:32AM
Nov 1, 2018 04:05PM Exelixis Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 22, 2018 06:50AM
Oct 22, 2018 06:45AM
Oct 22, 2018 06:17AM
Oct 20, 2018 08:45AM
Oct 8, 2018 06:05PM
Oct 8, 2018 08:05AM
Oct 8, 2018 08:00AM Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
Sep 21, 2018 05:54AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All